Objectives. Invasion of differentiated thyroid cancer (DTC) into surrounding structures can lead to morbid procedures such as\nlaryngectomy and tracheal resection. In these patients, there is a potential role for neoadjuvant therapy. Methods. We identified\nthree studies involving the treatment of DTC with neoadjuvant chemotherapy: two from Slovenia and one from Japan. Results.\nThese studies demonstrate that in selected situations, neoadjuvant chemotherapy can have a good response and allow for a more\ncomplete surgical resection, the treatment of DTC. Additionally, the SELECT trial shows that the targeted therapy lenvatinib is\neffective in the treatment of DTC and could be useful as neoadjuvant therapy for this disease due to its short time to response.\nPazopanib has also demonstrated promise in phase II data. Conclusions. Thus, chemotherapy in the neoadjuvant setting could\npossibly be useful for managing advanced DTC. Additionally, some of the new tyrosine kinase inhibitors (TKIs) hold promise for\nuse in the neoadjuvant setting in DTC.
Loading....